1. T-lymphocytes response persists following Plasmodium berghei strain Anka infection resolution and may contribute to later experimental cerebral malaria outcomes.
- Author
-
de Miranda AS, Ferreira RN, Vieira ÉLM, Abreu LKS, Brant F, Vieira LB, Ribeiro FM, Machado FS, Rachid MA, and Teixeira AL
- Subjects
- Animals, Dizocilpine Maleate pharmacology, Dizocilpine Maleate therapeutic use, Excitatory Amino Acid Antagonists pharmacology, Excitatory Amino Acid Antagonists therapeutic use, Female, Mice, Mice, Inbred C57BL, T-Lymphocytes drug effects, Treatment Outcome, Malaria, Cerebral drug therapy, Malaria, Cerebral immunology, Plasmodium berghei drug effects, Plasmodium berghei immunology, T-Lymphocytes immunology
- Abstract
Several studies have proposed cerebral malaria (CM) as a CD4+ and CD8+ T lymphocyte-mediated disease. However, there are no data regarding the recruitment and/or persistence of these cells in the CNS following the phase of infection resolution. Glutamate-mediate excitotoxicity has also been implicated in CM. Blockade of glutamate NMDA receptors by its noncompetitive antagonist MK801 modulates cytokine and neurotrophic factors expression preventing cognitive and depressive-like behavior in experimental CM. Herein, we aim to investigate the role of T lymphocytes in later outcomes in CM, and whether the protective role of MK801 is associated with T lymphocytes response., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF